Stochastic cellular automata model and Monte Carlo simulations of CD4+ T cell dynamics with a proposed alternative leukapheresis treatment for HIV/AIDS

Computers in Biology and Medicine

Volumn 41, Issue 7, 2011, Pages 546-558

  Precharattana, Monamorn ^a   Nokkeaw, Arthorn ^a,b   Triampo, Wannapong ^a,b   Triampo, Darapond ^a   Lenbury, Yongwimon ^a,c  

^a Mahidol University   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c PERDO   (Thailand)

Author keywords

AIDS; CD4+ T cells; Cellular automata; HIV; Leukapheresis; Monte Carlo simulations; Stochastic process

Indexed keywords

AIDS; HIV; LEUKAPHERESIS; MONTE CARLO SIMULATION; STOCHASTIC PROCESS; T CELLS;

AUTOMATA THEORY; CELL CULTURE; CELL PROLIFERATION; CELLS; CELLULAR AUTOMATA; COMPUTER SIMULATION; DRUG THERAPY; INVESTMENTS; MONTE CARLO METHODS; PATTERN RECOGNITION SYSTEMS; RANDOM PROCESSES; STOCHASTIC MODELS; STOCHASTIC SYSTEMS; TISSUE;

DISEASES;

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; COMPUTER SIMULATION; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKAPHERESIS; LYMPH NODE; LYMPHOID CELL; LYMPHOID TISSUE; MONTE CARLO METHOD; PRIORITY JOURNAL; STOCHASTIC MODEL;

CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKAPHERESIS; MODELS, IMMUNOLOGICAL; MONTE CARLO METHOD; STOCHASTIC PROCESSES; SYSTEMS BIOLOGY;

EID: 80955179040     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2011.05.005     Document Type: Article

References (65)

1. W.H.O. Unaids, A. E. update. Geneva: UNAIDS, WHO (2007).
2. Clifford D.B., Yiannoutsos C., Glicksman M., Simpson D.M., Singer E.J., Piliero P.J., Marra C.M., Francis G.S., McArthur J.C., Tyler K.L., Tselis A.C., Hyslop N.E. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52:623-625.
3. Albrecht H., Hoffmann C., Degen O., Stoehr A., Plettenberg A., Mertensk tter T., Eggers C., Stellbrink H.J. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998, 12:1149-1154.
4. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., Kumar P.N., Mintz L., Wallach F.R., Nemo G.J. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 2001, 135:17-26.
5. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338:853-860.
6. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L., Telenti A., Vernazza P.L., Bernasconi E., Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?. JAIDS-J. Acq. Imm. Def. 1999, 21:114-119.
7. Maisels L., Steinberg J., Tobias C. An investigation of why eligible patients do not receive HAART. Aids Patient Care St. 2001, 15:185-191.
8. Tabuchi T., Ubukata H., Saniabadi A.R., Soma T. Granulocyte apheresis as a possible new approach in cancer therapy: a pilot study involving two cases. Cancer Detect. Prev. 1999, 23:417-421.
9. Yonekawa M., Kawamura A., Komai T., Agishi T., Adachi M. Extracorporeal granulocytapheresis for cancer and rheumatoid arthritis. Transfus. Sci. 1996, 17:463-472.
10. Tabuchi T., Ubukata H., Sato S., Nakata I., Goto Y., Watanabe Y., Hashimoto T., Mizuta T., Adachi M., Soma T. Granulocytapheresis as a possible cancer treatment. Ther. Apher. 2001, 4:155-160.
11. Sawada K., Ohnishi K., Kosaka T., Chikano S., Yokota Y., Egashira A., Izawa H., Yamamura M., Amano K., Satomi M., Shimoyama T. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther. Apher. Dial. 1997, 1:207-211.
12. Sandborn W.J. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12:S15-S21.
13. Furuta T., Hotta O., Yusa N., Horigome I., Chiba S., Taguma Y. Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment. Lancet 1998, 352:203-204.
14. Matsui T., Nishimura T., Matake H., Ohta T., Sakurai T., Yao T. Granulocytapheresis for Crohns disease: a report on seven refractory patients. Am. J. Gastroenterol. 2003, 98:511-512.
15. Miyamoto H., Okahisa T., Iwaki H., Murata M., Ito S., Nitta Y., Akutagawa M., Kinouchi Y., Ohnishi Y., Oto J., Nishimura M. Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics. Ther. Apher. Dial. 2007, 11:16-21.
16. Sawada K., Ohnishi K., Fukunaga K., Shimoyama T. A new treatment for HCV-ulcerative colitis comorbidity intolerant to INF-α. Am. J. Gastroenterol. 2004, 98:228-229.
17. Diepolder H.M., Kashiwagi N., Teuber G., Ulsenheimer A., Franz M., Yokoyama T., Zachoval R. Leucoytapheresis with Adacolumn (R) enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1. J. Med. Virol. 2005, 77:209-215.
18. Lazzarin A., Clerici M., Hasson H., Fumagalli L., Ferrante P., Saniabadi A.R., Adachi M., Beretta A. Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis. J. Clin. Apheresis 2001, 16:35-36.
19. Beretta A., Clerici M., Hasson H., Fumagalli L., Trabattoni D., Lillo F., Ferrante P., Saniabadi A.R., Adachi M., Lazzarin A. Ex-vivo purging of circulating monocytes results in immunovirologic improvement in partially HAART responder HIV-infected patients. J. Biol. Regul. Homeost. Agents 2000, 14:27-31.
20. Beretta A., Hasson H., Samiabadi A., Alfano M., Trabattoni D., Lillo F., Ferrante P., Clerici M., Lazzarin A. Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters. Perfusion 2002, 17:47-51.
21. Hasson H., Saniabadi A., Alfano M., Trabattoni D., Ferrante P., Lillo F., Clerici M., Lazzarin A., Beretta A. Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART. J. Biol. Regul. Homeost. Agents 2002, 16:58-63.
22. Schnittman S.M., Psallidopoulos M.C., Lane H.C., Thompson L., Baseler M., Massari F., Fox C.H., Salzman N.P., Fauci A.S. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989, 245:305-308.
23. Schacker T., Little S., Connick E., Gebhard K., Zhang Z., Krieger J., Pryor J., Havlir D., Wong J., Schooley R.T., Richman D., Corey L., Haase A.T. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J. Infect. Dis. 2001, 183:555-562.
24. Briones C., Domingo E., Molina-Parós C. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J. Mol. Biol. 2003, 331:213-229.
25. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
26. Ho D.D. Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J. Clin. Invest. 1997, 99:2565-2567.
27. Suemitsu J., Yoshida M., Yamawaki N., Yamashita Y. Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter. Ther. Apher. Dial. 1998, 2:31-36.
28. Shibata H., Kuriyama T., Yamawaki N. Cellsorba. Ther. Apher. Dial. 2003, 7:44-47.
29. Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther. Apher. 2002, 6:261-266.
30. Sugi K. Filtration leukocytapheresis expected to ulcerative colitis treatment. Bio Clinica 1997, 12:339-342.
31. Pantaleo G., Graziosi C., Demarest J.F., Butini L., Montroni M., Fox C.H., Orenstein J.M., Kotler D.P., Fauci A.S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
32. Zhang L., Ramratnam B., Tenner-Racz K., He Y., Vesanen M., Lewin S., Talal A., Racz P., Perelson A.S., Korber B.T., Markowitz M., Guo Y., Duran M., Hurley A., Tsay J., Huang Y., Wang C., Ho D.D. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 1999, 340:1605-1613.
33. Orenstein J.M., Fox C., Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276:1857-1861.
34. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.A., Melroe H., Cavert W., Gebhard K., Staskus K., Zhang Z., Dailey P.J., Balfour.H.H., Erice A., Perelson A.S. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-988.
35. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
36. Nowak M.A., May R. Virus Dynamics: Mathematical Principles of immunology and Virology 2000, Oxford University Press, USA.
37. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2002, 2:28-36.
38. Perelson A.S., Nelson P.W. Mathematical analysis of HIV-I: dynamics in vivo. SIAM Rev. 1999, 41:3-44.
39. Stafford M.A., Corey L., Cao Y., Daar E.S., Ho D.D., Perelson A.S. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 2000, 203:285-301.
40. Pantaleo G., Graziosi C., Butini L., Pizzo P.A., Schnittman S.M., Kotler D.P., Fauci A.S. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1991, 88:9838-9842.
41. Cohen O.J., Pantaleo G., Lam G.K., Fauci A.S. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin. Immunopathol. 1997, 18:305-322.
42. Hood L.E., Weissmann I.L., Wood W.B., Wilson J.H. Immunology 1984, The Benjamin/Cummings Publishing Company, Menlo Park, CA.
43. Wolfram S. Statistical mechanics of cellular automata. Rev. Mod. Phys. 1983, 55:601-644.
44. Wolfram S. Universality and complexity in cellular automata. Physica D 1984, 10:1-35.
45. Zorzenon dos Santos R.M., Coutinho S. Dynamics of HIV infection: A cellular automata approach. Phys. Rev. Lett. 2001, 87:168102.
46. Shi V., Tridane A., Kuang Y. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment. J. Theor. Biol. 2008, 253:24-35.
47. Burkhead E.G., Hawkins J.M., Molinek D.K. A dynamical study of a cellular automata model of the spread of HIV in a lymph node. Bull. Math. Biol. 2009, 71:25-74.
48. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., Polis M.A., Haase A.T., Feinberg M.B., Sullivan J.L., Jamieson B.D., Zack J.A., Picker L.J., Koup R.A. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
49. Pantaleo G., Fauci A.S. Immunopathogenesis of HIV infection 1. Annu. Rev. Microbiol. 1996, 50:825-854.
50. Weber J. The pathogenesis of HIV-1 infection. Br. Med. Bull. 2001, 58:61-72.
51. Pantaleo G., Graziosi C., Demarest J.F., Cohen O.J., Vaccarezza M., Gantt K., Muro-Cacho C., Fauci A.S. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol. Rev. 1994, 140:105-130.
52. Tindall B., Cooper D.A. Primary HIV infection: host responses and intervention strategies. AIDS 1991, 5:1-14.
53. Daar E.S., Moudgil T., Mayer R.D., Ho D.D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1991, 324:961-964.
54. Pehrson P.O., Lindbäck S., Lidman C., Gaines H., Giesecke J. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS 1997, 11:1007-1012.
55. Goulder P., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., luzzi G., Morgan B., Edwards A., McMichael A.J., Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med 1997, 3:212-217.
56. Klenerman P., Rowland-Jones S., McAdam S., Edwards J., Daenke S., lalloo D., Köppe B., Rosenberg W., Boyd D., Edwards A., Giangrande P., Phillips R.E., McMichael A.J. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994, 369:403-407.
57. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
58. Ramratnam B., Mittler J.E., Zhang L., Boden D., Hurley A., Fang F., Macken C.A., Perelson A.S., Markowitz M., Ho D.D. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 2000, 6:82-85.
59. Pierratos A., Ouwendyk M., Francoeur R., Vas S., Raj D.S., Ecclestone A.M., Langos V., Uldall R. Nocturnal hemodialysis: three-year experience. J. Am. Soc. Nephrol. 1998, 9:859-868.
60. Schiffl H., Lang S.M., Fischer R. Daily hemodialysis and the outcome of acute renal failure. N. Engl. J. Med. 2002, 346:305-310.
61. Williams A.W., Chebrolu S.B., Ing T.S., Ting G., Blagg C.R., Twardowski Z.J., Woredekal Y., Delano B., Gandhi V.C., Kjellstrand C.M. Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis" (6 dialyses per week). Am. J. Kidney Dis. 2004, 43:90-102.
62. Pierratos A. New approaches to hemodialysis. Annu. Rev. Med. 2004, 55:179-189.
63. Galland R., Traeger J., Arkouche W., Cleaud C., Delawari E., Fouque D. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int. 2001, 60:1555-1560.
64. Locatelli F., Buoncristiani U., Canaud B., Kohler H., Petitclerc T., Zucchelli P. Dialysis dose and frequency. Nephrol. Dial. Transplant 2005, 20:285-296.
65. Blagg C.R., Kjellstrand C.M., Ting G.O., Young B.A. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. Hemodial. Int. 2006, 10:371-374.